Sarepta Therapeutics Inc (SRPT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.46 is considered Undervalued compared with the five-year average of 6.42. The fair price of Sarepta Therapeutics Inc (SRPT) is between 58.70 to 109.55 according to relative valuation method. Compared to the current price of 16.32 USD , Sarepta Therapeutics Inc By Undervalued By 72.2%.

Relative Value

Fair Zone

58.70-109.55

Current Price：16.32

72.2%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Sarepta Therapeutics Inc (SRPT) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Sarepta Therapeutics Inc (SRPT) has a current Price-to-Book (P/B) ratio of 1.69. Compared to its 3-year average P/B ratio of 10.17, the current P/B ratio is approximately -83.37% higher. Relative to its 5-year average P/B ratio of 11.73, the current P/B ratio is about -85.58% higher. Sarepta Therapeutics Inc (SRPT) has a Forward Free Cash Flow (FCF) yield of approximately -17.07%. Compared to its 3-year average FCF yield of -8.91%, the current FCF yield is approximately 91.48% lower. Relative to its 5-year average FCF yield of -8.19%, the current FCF yield is about 108.48% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for SRPT competitors is 10.61, providing a benchmark for relative valuation. Sarepta Therapeutics Inc Corp (SRPT.O) exhibits a P/S ratio of 1.46, which is -86.24% above the industry average. Given its robust revenue growth of -32.73%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of SRPT increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of SRPT in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is SRPT currently overvalued or undervalued?

Sarepta Therapeutics Inc (SRPT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.46 is considered Undervalued compared with the five-year average of 6.42. The fair price of Sarepta Therapeutics Inc (SRPT) is between 58.70 to 109.55 according to relative valuation method. Compared to the current price of 16.32 USD, Sarepta Therapeutics Inc is Undervalued By 72.20%.

What is Sarepta Therapeutics Inc (SRPT) fair value?

SRPT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Sarepta Therapeutics Inc (SRPT) is between 58.70 to 109.55 according to relative valuation method.

How does SRPT's valuation metrics compare to the industry average?

The average P/S ratio for SRPT's competitors is 10.61, providing a benchmark for relative valuation. Sarepta Therapeutics Inc Corp (SRPT) exhibits a P/S ratio of 1.46, which is -86.24% above the industry average. Given its robust revenue growth of -32.73%, this premium appears unsustainable.

What is the current P/B ratio for Sarepta Therapeutics Inc (SRPT) as of Mar 03 2026?

As of Mar 03 2026, Sarepta Therapeutics Inc (SRPT) has a P/B ratio of 1.69. This indicates that the market values SRPT at 1.69 times its book value.

What is the current FCF Yield for Sarepta Therapeutics Inc (SRPT) as of Mar 03 2026?

As of Mar 03 2026, Sarepta Therapeutics Inc (SRPT) has a FCF Yield of -17.07%. This means that for every dollar of Sarepta Therapeutics Inc's market capitalization, the company generates -17.07 cents in free cash flow.

What is the current Forward P/E ratio for Sarepta Therapeutics Inc (SRPT) as of Mar 03 2026?

As of Mar 03 2026, Sarepta Therapeutics Inc (SRPT) has a Forward P/E ratio of 89.24. This means the market is willing to pay $89.24 for every dollar of Sarepta Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Sarepta Therapeutics Inc (SRPT) as of Mar 03 2026?

As of Mar 03 2026, Sarepta Therapeutics Inc (SRPT) has a Forward P/S ratio of 1.46. This means the market is valuing SRPT at $1.46 for every dollar of expected revenue over the next 12 months.

SRPT Valuation